5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer;Chimiothérapie des adénocarcinomes du pancreas non résécables par 5-fluorouracile, acide folinique et cisplatine (LV5FU2-P)

Gastroenterologie Clinique et Biologique

Volumn 26, Issue 6-7, 2002, Pages 605-609

  Taïeb, Julien ^a,c   Lecomte, Thierry ^b   Ezenfis, Joël ^a   Artru, Pascal ^b   Mitry, Emmanuel ^b   Boige, Valérie ^a   Clavero Fabri, Marie Christine ^b   Vaillant, Jean Nicolas ^b   Rougier, Philippe ^b   Ducreux, Michel ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PANCREAS CANCER; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FLUOROURACIL; GASTROINTESTINAL DISEASES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEUTROPENIA; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 17544403541     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Adénocarcinome du pancréas. Caractères généraux
2. Pancreatic carcinoma
3. Cancer of the pancreas. 50 Years of surgery
4. Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas
5. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma
6. Activity of cisplatin in adenocarcinoma of the pancreas
7. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer
8. Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study
9. Efficacy of 5FU+Cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC): A randomized trial from the French Anticancer Centers Digestive Group (FNLCCDG)
10. Reporting results of cancer treatment
11. Optimal two-stage designs for phase II clinical trials
12. Perspectives in chemotherapy of pancreatic cancer
13. No standard treatment is available for advanced pancreatic cancer
14. Multidrug resistance: A solvable problem?
15. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
16. Chemotherapy prolongs survival in inoperable pancreatic carcinoma
17. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
18. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line
19. Neoadjuvant Cisplatinum, Leucovorin and Fluorouracil (PLF) in adequately staged patients with locally advanced gastric carcinoma
20. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma
21. Résultats d'une étude de phase II randomisée comparant une chimiothérapie par 5-FU-acide-l-folinique-cisplatine (FLP) au 5-FU continu-cisplatine (FP) dans les carcinomes métastatiques de l'oesophage, de l'estomac et du pancréas (essai FFCD 9404)
22. Clinical benefit with cisplatin, hydroxyurea and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma
23. A phase II study: Docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma
24. Randomized phase II study of oxaliplatin alone (OXA), 5-Fluorouracil (5FU) alone, and the two drugs combined (OXA-FU) in advanced or metastatic pancreatic adenocarcinoma (APC)
25. Gemcitabine-oxaliplatin combination in advanced pancreatic carcinoma: A gercor multicenter phase II study
26. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma